Find out how researchers are applying Illumina technology.
NICHOLAS NAVIN, Ph.D. Assistant Professor in the Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas
“Tools like the Nextera Rapid Capture Exome kit are allowing researchers to get a whole new view of tumors and their genetic diversity and complexity.”
Dr. Thomas Sutter, Ph.D. Director of the W. Harry Feinestone Center for Genomic Research and Feinestone Chair of Molecular Biology at the University of Memphis
"Nextera XT allows our researchers to spend less time making libraries and more time making discoveries."
ALAN LEMMON, Ph.D. Assistant Professor, Department of Scientific Computing, Florida State University
"We found that we can perform a phylogenetic project for ~1% of the cost of traditional PCR + Sanger approaches and ~5% of the cost of modern Amplicon + NGS approaches."
BYUNG-KWAN CHO, Ph.D. Associate Professor, Center for Reproductive Medicine, Weill Cornell Medical College of Cornell University
"Offering a single sample format, MiSeq gives us speed. It's one of the system's best features."
KANGPU XU, Ph.D. Full Professor and Canada Research Chair in Medical Genomics, Infectious Disease Research Center, Faculty of Medicine, Centre Hospitalier Université Laval (CHUL)
"We need a procedure that can be completed in 12 hours. We use the Nextera kits to cut the library prep from one day to half a day, saving 4 or 5 hours."
ELIOT SHEARER Predoctoral Research Fellow, M.D./Ph.D. Program, University of Iowa Carver College of Medicine
"Our goal is to run all 66 genes on the MiSeq system with an overall turnaround time of two to three months, compared to running one gene in the same amount of time with Sanger sequencing."
GRAHAM TAYLOR, Ph.D. FRCPath Translational Genomics Unit, Leeds University President of the Human Genome Variation Society
"MiSeq has a very simple workflow…We don't lose any time preparing emulsion PCR libraries."
ANDREW FELLOWES, Ph.D., FHGSA, FFSc (RCPA) Scientist in Charge, Molecular Pathology Diagnostic Development, Department of Pathology, Peter MacCallum Cancer Centre
"MiSeq and TruSeq Custom Amplicon introduce huge advantages in simplifying and streamlining the workflow, enabling us to deliver results within a clinically relevant time frame."
DAVID BUCK, Ph.D. Head of High-Throughout Genomics, Wellcome Trust Centre for Human Genetics, University of Oxford
"I think we can start referring to the data that's generated on MiSeq as the new gold standard."
TIM STINEAR, Ph.D. Principal Research Fellow, Department of Microbiology and Immunology, University of Melbourne
"You are getting significantly more data and higher quality data from a MiSeq run."
BRYAN PAEPER Research Consultant, Northwest Genomics Center, University of Washington
"MiSeq does exactly what it's supposed to. It works in the specified amount of time. It produces the specified data quality. I've actually been really impressed."
JAMES HADFIELD Genomics Core Director, Cambridge Research Institute
"Quite simply, we'll be able to do projects that we would have held off doing in the past such as single-end, long-read sequencing, and method development."
JACOB KITZMAN Doctoral Candidate, Department of Genome Sciences at University of Washington
“The MiSeq turnaround time is excellent and the throughput is high. It gives us confidence in whether our library is going to be good or not, saving us money and helping prioritize samples for the HiSeq.”
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina's innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.